10-Q: GRAIL Q2 2025: Revenue Up, Losses Narrow Amid Restructuring

GRAIL, Inc. reports an 11% increase in total revenue for Q2 2025, driven by Galleri sales volume, while significantly narrowing net losses and continuing strategic restructuring efforts.

Summary

• Total revenue for the three months ended June 30, 2025, increased 11% to $35.5 million, up from $32.0 million in the same period of 2024.
• Screening revenue, primarily from Galleri sales, rose 22% to $34.4 million in Q2 2025, driven by a 29% increase in Galleri sales volume, though average selling price (ASP) decreased by 6%.
• Net loss significantly narrowed to $114.0 million in Q2 2025, a substantial improvement from $1.6 billion in Q2 2024, primarily due to a lower goodwill and intangible asset impairment charge.
• Adjusted EBITDA improved to $(78.3) million in Q2 2025, compared to $(139.4) million in Q2 2024.
• Operating expenses saw significant reductions: Research and development decreased 51% to $46.6 million, sales and marketing decreased 30% to $28.5 million, and general and administrative expenses decreased 44% to $37.9 million, largely due to the 2024 restructuring plan and reduced legal fees post-Spin-Off.
• A goodwill and intangible asset impairment charge of $28.0 million was recorded in Q2 2025, leading to the write-off of the entire in-process research and development (IPR&D) asset carrying value.
• As of June 30, 2025, cash, cash equivalents, and restricted cash totaled $130.8 million, with short-term marketable securities at $475.3 million, providing sufficient liquidity for at least the next 12 months.

Sentiment

Score: 7

Explanation: The company demonstrated significant financial improvements with narrowed losses and increased revenue, driven by strong Galleri sales volume and effective restructuring. Positive clinical trial data reinforces product validation. However, continued operating losses, the need for future capital, and the impairment of the IPR&D asset, along with regulatory uncertainties, temper the overall positive sentiment.

Positives

• Total revenue increased 11% to $35.5 million for the three months ended June 30, 2025, compared to $32.0 million in Q2 2024.
• Screening revenue increased 22% to $34.4 million in Q2 2025, driven by a 29% increase in Galleri sales volume.
• Net loss significantly narrowed to $114.0 million in Q2 2025 from $1.6 billion in Q2 2024.
• Adjusted EBITDA improved to $(78.3) million in Q2 2025 from $(139.4) million in Q2 2024, reflecting operational efficiencies.
• Research and development expenses decreased 51% to $46.6 million in Q2 2025, primarily due to workforce reductions and completion of clinical study enrollment.
• Sales and marketing expenses decreased 30% to $28.5 million in Q2 2025, attributed to restructuring efforts.
• General and administrative expenses decreased 44% to $37.9 million in Q2 2025, mainly from reduced legal and professional fees post-Spin-Off.
• Positive top-line performance and safety results from the PATHFINDER 2 study's first 25,578 participants demonstrated substantially greater additional cancer detection and higher positive predictive value (PPV) than the original PATHFINDER study, with consistent cancer signal of origin (CSO) accuracy and specificity.
• Data from the NHS-Galleri prevalent screening round showed substantially higher PPV, consistent CSO accuracy, and specificity compared to the PATHFINDER study, with no serious safety concerns.
• Real-world evidence from over 100,000 patients showed Galleri test performance consistent with prior clinical studies for asymptomatic screening, with a PPV of 49% and CSO accuracy of 87%.
• The SEC closed its investigation into Illumina's acquisition of GRAIL and related matters on May 9, 2025.
• The company believes its existing cash, cash equivalents, and short-term marketable securities ($606.1 million total) will be sufficient to meet working capital and capital expenditure needs for at least the next 12 months.

Negatives

• Development services revenue decreased 69% to $1.2 million for the three months ended June 30, 2025, compared to $3.8 million in Q2 2024.
• The company continues to incur net losses ($114.0 million in Q2 2025) and negative cash flows from operations ($172.0 million for the six months ended June 30, 2025).
• A goodwill and intangible assets impairment charge of $28.0 million was recognized in Q2 2025, resulting in the write-off of the entire IPR&D asset carrying value due to changes in market conditions and expected future cash flows.
• Galleri's average selling price (ASP) decreased by 6% in Q2 2025.
• The company has experienced and may continue to experience increased turnaround times, re-processing costs, and sample failures with the new automated Galleri platform launched in late 2024.
• The NHS determined not to initiate an implementation pilot in England for Galleri prior to the final NHS-Galleri trial results, based on early analysis of prevalent screening round data.
• The company anticipates needing to raise additional financing in the future to fund its operations.
• The company is restricted in its ability to raise money through certain transactions or with certain parties pursuant to the terms of the Tax Matters Agreement with Illumina.

Risks

• Products or future products may not perform as expected, and clinical study results may not support launch or use, or comply with regulatory requirements, or be replicated in later studies or real-world settings.
• Operational or technological failures in complex biochemical and bioinformatics processes or fluctuations in external variables may result in lower performance characteristics (sensitivity, specificity) or a higher number of test failures.
• Refinements to algorithms and other processes under development may inadvertently result in unanticipated issues that reduce performance characteristics or adversely affect test results.
• Uncertainty regarding the FDA's authority to regulate laboratory developed tests (LDTs) as medical devices following the LDT Final Rule Decision could lead to increased competition or require significant changes to the PMA application.
• The FDA or other regulators may require additional clinical data to support any clearance, approval, or certification, leading to delays, increased costs, or narrowed indications/labeling.
• Failure to successfully develop new and/or improved products (including new versions of existing products) on a timely basis could materially adversely affect results of operations and business.
• Bridging studies to compare enhanced product versions to existing ones may be unsuccessful or insufficient to support approval, potentially requiring reversion to existing versions and causing delays in PMA submission.
• Increased turnaround times, re-processing costs, and sample failures with the new automated Galleri platform could lead to reputational harm, lost customers, revenue, additional expenditures, or delays in PMA application.
• Preliminary or topline data from clinical studies are based on preliminary analysis and are subject to change following comprehensive review, audit, and verification procedures, potentially differing materially from final data.
• Regulatory agencies or other parties may not accept or agree with the company's assumptions, estimates, calculations, conclusions, or analyses of data, impacting product value and regulatory approval.
• Risks associated with tariffs and other trade and global macroeconomic restrictions, including economic weakness, political instability, challenges enforcing intellectual property rights, trade protection measures, changes in non-U.S. laws, exchange rate risk, and geopolitical actions.
• International expansion poses risks such as differing performance in non-U.S./U.K. populations, difficulties with in-country studies, and limitations by government partnerships or laboratory space.
• The company expects to incur operating losses for at least the next several years and will need to raise additional financing in the future.
• Future capital raises through equity or debt financing could result in dilution to existing stockholders, increased fixed payment obligations, or the existence of securities with rights senior to common stock.
• Incurring indebtedness could subject the company to covenants that restrict operations.
• Raising funds through collaborations and licensing arrangements may require relinquishing significant rights or granting licenses on unfavorable terms.

Future Outlook

The company expects to continue incurring operating losses for at least the next several years as it invests in research and development and seeks broad reimbursement for its commercialized products. Research and development expenses are projected to decrease over the next three years as investment in product programs beyond Galleri is reduced, and large clinical trials transition to data follow-up phases. Sales and marketing expenses are expected to decrease in the near term due to restructuring, then stabilize or increase, but decrease as a percentage of revenue over the next three years and long term. General and administrative expenses are also expected to decrease in the near term post-restructuring, then stabilize or increase, and decrease as a percentage of revenue over the next three years and long term. The company plans to submit a Premarket Approval (PMA) application to the FDA for Galleri in the first half of 2026, with final clinical utility results from the NHS-Galleri trial anticipated in mid-2026.

Management Comments

• We believe screening individuals for many types of cancer with a single test represents a significant opportunity to reduce the global burden of cancer.
• We plan to submit data from the prevalent screening round of the NHS-Galleri trial, the first 25,000 participants in the PATHFINDER 2 study, and a bridging study... as part of our PMA in the first half of 2026.
• Final clinical utility results from all three years of the trial are expected in mid-2026.
• We plan to continue to invest in our biopharmaceutical partnerships and work with our partners to leverage our proprietary methylation technology in precision oncology applications.
• We believe that our existing cash, cash equivalents and short-term marketable securities will be sufficient to meet our working capital and capital expenditure needs for at least the next 12 months, as of the date these unaudited condensed consolidated financial statements were filed.

Industry Context

The company operates in the multi-cancer early detection (MCED) market, a relatively novel and evolving technology sector. It is actively working to establish MCED as a critical solution for cancer screening. The regulatory landscape for laboratory developed tests (LDTs) is currently uncertain following the LDT Final Rule Decision, which could impact market competition and the company's regulatory strategy. The pursuit of FDA approval for Galleri is a key strategic move aimed at unlocking broader commercial payor coverage in the U.S. and facilitating adoption in other single-payor healthcare systems globally.

Comparison to Industry Standards

• In the PATHFINDER study, Galleri demonstrated a positive predictive value (PPV) of 43%, cancer signal of origin (CSO) accuracy of 88%, and specificity of 99.5%.
• The NHS-Galleri prevalent screening round showed a substantially higher PPV, consistent CSO accuracy, and specificity compared to the PATHFINDER study.
• The PATHFINDER 2 study's initial results showed substantially greater additional cancer detection and a higher PPV than the original PATHFINDER study, with consistent specificity and CSO accuracy.
• Real-world evidence from over 100,000 patients indicated Galleri test performance consistent with prior clinical studies for asymptomatic screening, with a PPV of 49% and CSO accuracy of 87%.
• The company believes it has designed and executed the largest clinical program in genomic medicine to date, encompassing studies like CCGA, NHS-Galleri, PATHFINDER, PATHFINDER 2, REACH/Galleri-Medicare, REFLECTION, STRIVE, SUMMIT, and SYMPLIFY.

Corporate Governance

Legal Proceedings

• The SEC investigation relating to Illumina's acquisition of GRAIL and certain statements/disclosures, and related to the conduct and compensation of certain management members, was closed on May 9, 2025.
• Federal Securities Class Actions (Kangas v. Illumina, Inc. et al., Roy v. Illumina, Inc. et al., Louisiana Sheriffs Pension & Relief Fund v. Illumina, Inc. et al.) were consolidated into In re Illumina, Inc. Securities Litigation No. 23-cv-2082-LL-MMP.
• The consolidated amended complaint alleges GRAIL, Illumina, and certain current/former directors/officers violated sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5 in connection with Illumina's acquisition of GRAIL and related disclosures.
• GRAIL has an indemnification obligation for certain current and former directors and officers involved in the federal securities class action.
• The company moved to dismiss the Lead Plaintiffs' second amended complaint on November 12, 2024, with the motion currently pending before the federal district court.
• The company denies the allegations in the complaints and intends to vigorously defend the litigation.
• As of June 30, 2025, the company is unable to estimate a range of possible loss in excess of the amounts accrued for legal matters.

Related Party Transactions

• Illumina retained a 12.5% ownership stake in GRAIL, holding 4,502,126 shares of common stock as of June 30, 2025.
• Illumina serves as both a customer and a major supplier of reagents and capital equipment to GRAIL.
• Screening revenue from Illumina was $52 thousand for Q2 2025 and $108 thousand for Q2 2024.
• Cost of screening revenue from Illumina was $1,176 thousand for Q2 2025 and $3,457 thousand for Q2 2024.
• Cost of development services revenue from Illumina was $19 thousand for Q2 2025 and $71 thousand for Q2 2024.
• Research and development expenses from Illumina were $578 thousand for Q2 2025 and $5,310 thousand for Q2 2024.
• General and administrative expenses from Illumina were $0 for Q2 2025 and $52 thousand for Q2 2024.
• GRAIL has agreed to pay Illumina a high single-digit royalty on net sales generated by its products or revenues in the field of oncology, subject to certain reductions, in perpetuity.
• The royalty arrangement with Illumina is suspended until the earlier of December 24, 2026, or any earlier GRAIL Change of Control.
• GRAIL received $932.3 million in disposal funding from Illumina on June 21, 2024, which is subject to a clawback feature if certain transactions occur prior to September 24, 2025.
• The Tax Matters Agreement with Illumina includes restrictions on GRAIL to preserve the tax-free status of the Spin-Off, with a breach potentially resulting in liability for specific separation taxes.

Stakeholder Impact

• Shareholders: Potential for increased value from successful commercialization and regulatory approval of Galleri, but also face potential dilution from future capital raises, impact from ongoing federal securities class action litigation, and increased reporting requirements as the company ceases to be an EGC.
• Employees: Experienced workforce reductions (approximately 30% headcount reduction in 2024) due to the restructuring plan, but also benefit from stock-based compensation plans (2024 Incentive Award Plan, 2024 Inducement Award Plan, Employee Stock Purchase Plan).
• Customers: Benefit from the continued availability of Galleri and the potential for broader access and lower pricing with future FDA approval and reimbursement, but may experience increased turnaround times or sample failures with the new automated platform.
• Illumina (as a shareholder and partner): Retains a 12.5% stake in GRAIL, stands to receive royalty payments (after suspension period), and is subject to a clawback feature on the disposal funding provided.
• Regulatory Bodies (FDA, SEC): Ongoing interactions with the FDA for PMA submission, SEC investigation into past acquisition closed, and involvement in legal proceedings related to past acquisition.

Next Steps

• Complete registrational studies for Galleri.
• Submit Premarket Approval (PMA) application to the U.S. FDA in the first half of 2026.
• Await final clinical utility results from all three years of the NHS-Galleri trial in mid-2026.
• Continue to invest in biopharmaceutical partnerships and leverage proprietary methylation technology in precision oncology applications.
• Monitor and evaluate laboratory operations and performance to achieve intended sample processing metrics and costs, particularly for the new automated Galleri platform.
• Submit detailed results from the pre-specified analysis of the first 25,000 patients in the PATHFINDER 2 study for presentation at the European Society for Medical Oncologists Congress 2025.
• Evaluate the potential impact of new accounting guidance, specifically ASU No. 2023-09 (Income Taxes) and ASU No. 2024-03 (Expense Disaggregation Disclosures).
• Monitor the potential impact of the H.R.1, One Big Beautiful Bill Act, as additional guidance becomes available.

Key Dates

Recommendation

GRAIL's Q2 2025 results present a mixed picture. While the company demonstrated significant financial improvements with narrowed net losses and increased screening revenue driven by strong Galleri sales volume, operational efficiencies from restructuring, and positive clinical trial data, it continues to operate at a net loss and anticipates needing future capital raises. The impairment of the IPR&D asset and ongoing regulatory uncertainties surrounding LDTs and FDA approval pathways present notable risks. The stock may experience volatility based on future clinical data releases, regulatory milestones, and capital market activities. A 'Hold' recommendation is appropriate as the strong operational progress and product validation are balanced by the inherent risks of an early-stage commercial company in a novel, evolving market with significant capital needs. Investors should closely monitor progress on FDA approval, reimbursement, and cash burn.

Keywords

Multi-cancer early detection, MCED, Galleri, Cancer screening, Liquid biopsy, Genomic medicine, Diagnostic aid for cancer, DAC, Minimal residual disease, MRD, Clinical trials, NHS-Galleri, PATHFINDER, PATHFINDER 2, FDA approval, PMA, LDT, SEC filing, 10-Q, Financial results, Biotechnology, Diagnostics, Healthcare, GRAL, Illumina, Spin-off, Restructuring